A PHASE-II TRIAL OF ILMOFOSINE IN NONSMALL CELL BRONCHOGENIC-CARCINOMA

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyeth yl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcin oma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m(2)/day. Toxicities were gastrointestinal (nausea, vomiting, d iarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone mallow suppression was seen. No tumor regressions occ urred in 14 evaluable patients including 5 with no prior therapy. We c onclude that ilmofosine is inactive in this tumor at this dose and sch edule.